Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
about
Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adultsDirect Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.Safety and tolerability of pneumococcal vaccines in children.Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
P2860
Q24193819-961B2093-BC52-4686-AE90-266BB377A168Q35867061-4B0974F8-9A2D-425E-BA10-B86FB595D82AQ36256464-BF006FAA-612C-4AC8-ADA8-23D0768AA1BCQ37384762-0717CB9F-392B-4B75-953F-5ABCABB1D7D1Q37954709-92EE7D1C-15EE-4E27-BE66-34B97579234DQ38246355-D097DB82-301B-438D-BB1E-48BA794B5421Q38753554-6CCBC31D-FC4A-48F4-B3B8-B9F488C89CFEQ39939000-AD01B43C-E404-46DF-998F-31F07DED83D7Q54416744-A6732A49-A0C2-471B-9AB8-B13E95298F0F
P2860
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Safety and immunogenicity of a ...... children aged 12 to 16 months.
@en
type
label
Safety and immunogenicity of a ...... children aged 12 to 16 months.
@en
prefLabel
Safety and immunogenicity of a ...... children aged 12 to 16 months.
@en
P2093
P1476
Safety and immunogenicity of a ...... children aged 12 to 16 months.
@en
P2093
Aino Karvonen
Ilse Dieussaert
Lode Schuerman
Niklas Lindblad
Patricia Lommel
Paul Willems
Tiina Korhonen
Timo Vesikari
P304
P356
10.1097/INF.0B013E3181DFFABF
P577
2010-06-01T00:00:00Z